Managed Asset Portfolios LLC raised its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 0.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,617,541 shares of the company’s stock after acquiring an additional 4,069 shares during the quarter. Takeda Pharmaceutical comprises 3.2% of Managed Asset Portfolios LLC’s holdings, making the stock its 14th largest position. Managed Asset Portfolios LLC’s holdings in Takeda Pharmaceutical were worth $23,001,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently bought and sold shares of TAK. EverSource Wealth Advisors LLC lifted its holdings in shares of Takeda Pharmaceutical by 38.6% during the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after buying an additional 859 shares in the last quarter. Smithfield Trust Co increased its position in Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after acquiring an additional 1,490 shares during the period. Headlands Technologies LLC acquired a new stake in Takeda Pharmaceutical in the 2nd quarter worth about $59,000. Hexagon Capital Partners LLC boosted its holdings in Takeda Pharmaceutical by 34.3% in the 3rd quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock valued at $63,000 after purchasing an additional 1,129 shares during the period. Finally, Blue Trust Inc. boosted its holdings in Takeda Pharmaceutical by 74.0% in the 2nd quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock valued at $76,000 after purchasing an additional 2,330 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.
Takeda Pharmaceutical Stock Up 0.4 %
Shares of TAK opened at $13.38 on Friday. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08. The firm’s 50 day moving average is $14.10 and its 200-day moving average is $13.84. The stock has a market capitalization of $42.57 billion, a PE ratio of 23.07, a P/E/G ratio of 0.25 and a beta of 0.54.
Takeda Pharmaceutical Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Read More
- Five stocks we like better than Takeda Pharmaceutical
- What is the Shanghai Stock Exchange Composite Index?
- Disney’s Magic Strategy: Reinventing the House of Mouse
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- What is the Euro STOXX 50 Index?
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.